FDA clears C2N Diagnostics’ early Alzheimer’s assessment test
<p>C2N’s Alzheimer’s test is the first to be FDA-cleared for use in patients as young as 40 who present with cognitive impairment symptoms.</p> <p>The post <a href="https://www.medicaldevice-network.com/news/fda-clears-c2n-diagnostics-early-alzheimer-assessment-test/">FDA clears C2N Diagnostics’ early Alzheimer’s assessment test</a> appeared first on <a href="https://www.medicaldevice-network.com">Medical Device Network</a>.</p>